More Intelligent
Healthcare for All
with Single Molecule Diagnostics
At the Forefront of
Disease Detection
Our proprietary Quantitative Counting Templates, or QCTs™, power our ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. Several common and severe recessive conditions screened for prenatally can be caused by single-base pair alterations.
Our QCT technology enables quantifying these tiny variations using cell-free DNA. We believe this quantification will open the door to exponential improvements in prenatal screening, liquid biopsy, and beyond.
Moving Prenatal Screening and Oncology Testing Forward
We assess fetal risk for recessive conditions and aneuploidies from maternal blood.
UNITY Complete® includes a carrier screen as well as a single-gene (for recessive conditions) and aneuploidy NIPT and only requires a maternal blood draw at 9+ weeks to assess fetal risk.
Northstar Select™ and Northstar Response™ are now available for commercial use.
Northstar Select™ helps determine the most appropriate first line therapy, and Northstar Response™ helps monitor if the therapy is working.
"BillionToOne's leadership values growth of the company's employees and equality among peers."
Coupling Careers with Great Culture
What unites our team and drives us forward is one goal of making molecular testing more accurate, efficient, and accessible to all. This special group of bright and talented people is improving healthcare. If this appeals to you, consider joining us.
Leading with Passion and Purpose
Co-founders Oguzhan Atay, PhD, and David Tsao, PhD, and our team of engineers, scientists, and industry experts care deeply about every sample that comes into our lab.
Challenge the status quo that makes healthcare expensive, opaque and out of reach for most.
